Publication: BioSpace
Abstract
The FDA recently stated they will now accept a single pivotal clinical trial to support drug approval. This BioSpace article explores how the shift away from the traditional two-trial model is changing drug development strategy.
Rather than lowering the bar, a single pivotal trial concentrates risk and demands stronger planning, tighter data controls and more comprehensive evidence. This article highlights how companies are adapting by investing in risk-based quality management, real-time data monitoring, and advanced analytics tools, including artificial intelligence.
Published: 2026 年 3 月 10 日
Learn more about Strategic Regulatory Affairs Consulting Services
Certara’s Regulatory Affairs Consulting services leverage data-driven insights and advanced technology to optimize your regulatory submissions, ensuring timely approvals and successful market entry. Our expertise spans global regulatory agencies, including the FDA, EMA, MHRA, and more.
